Generic drug manufacturing: winning a launch window, then defending a collapsing price

The filing calendar is the business plan

Portfolio selection means predicting which originator products lose protection when, estimating how many competitors will file on the same molecule, and judging whether the formulation presents a technical barrier worth attempting. Products that are easy to copy attract crowds and lose their price quickly. Products with difficult formulations, awkward delivery devices or hard-to-source ingredients attract fewer entrants and hold value longer. That judgement is made years ahead of any revenue, with development spend committed against a forecast of competitor behaviour that nobody can verify until launch day arrives. Portfolios are therefore built as a spread of bets across timing and difficulty, on the assumption that several will disappoint.

Bioequivalence is the product development

There is no novel molecule to discover; the technical work is producing a formulation that behaves in the body like the reference product, then demonstrating it in human studies. That sounds routine and often is not, particularly for poorly soluble drugs, modified release forms and anything involving an inhaler, patch or injector. A failed study is expensive and puts the whole launch timing at risk. Sourcing the active ingredient with the right physical characteristics matters here too, since particle size and polymorphic form can decide whether a formulation matches the reference at all.

Ingredient sourcing concentration is the structural exposure

Much of the world's active ingredient production sits in a small number of countries and, for particular molecules, in a handful of plants. When one of those sites is suspended after an inspection or halts for environmental reasons, every finished dose manufacturer using it is affected simultaneously. Qualifying a second ingredient source requires stability data and a regulatory variation, so it must be done in advance to be useful. Firms that treat dual sourcing as an insurance policy worth funding tend to be the ones still supplying during a disruption, which is when tender contracts get re-awarded.

Price erosion rewrites the cost target after launch

Each additional entrant pushes price down, and in competitive tender markets the decline is steep and permanent. A product that was profitable at launch can become unviable within a few procurement cycles without anything changing inside the factory. Manufacturers respond by moving mature products onto larger batch sizes and cheaper sites, by exiting molecules where they cannot be among the low-cost suppliers, and by keeping a pipeline of newer launches to carry the margin. A portfolio without fresh launches decays, which is why development spending cannot be cut during a weak year without consequences later.

Tenders reward the lowest price and punish the stock-out

Buying is increasingly organised through tenders that award volume to one or two suppliers at a fixed price for a period. Winning brings scale; failing to supply brings penalties, reputational damage and sometimes exclusion from future rounds. That combination has an uncomfortable effect on resilience, because bidders price on the assumption that everything runs smoothly, leaving nothing to fund redundancy. Several persistent shortages of older, cheap medicines trace back to exactly this: too few suppliers, prices below the level that would justify investment, and no incentive to hold spare capacity.

Frequently asked questions

Why do generic prices fall so quickly after a molecule opens up?

Because the products are substitutable and buyers are organised. Once several approved suppliers exist, pharmacies, wholesalers and tender authorities can switch between them with little friction, so competition runs on price alone. Each entrant has already sunk its development cost and will accept a contribution over variable cost rather than sell nothing. The result is a rapid decline towards the cost base of the most efficient producer, after which the market stops attracting new entrants.

Why do generic manufacturers keep discontinuing older products?

Because at some point the price no longer covers the cost of keeping the product available. That cost includes not just manufacture but stability programmes, regulatory maintenance across markets, quality oversight and the changeover time the product consumes on shared equipment. A low-volume product on a busy site can displace something more profitable simply by occupying a campaign slot. Discontinuations concentrated on the same molecule are how shortages of cheap essential medicines begin.

What does integrating backwards into ingredient production actually buy?

Control of supply and of quality history, plus insulation from the price movements and inspection risk of external ingredient producers. It also captures margin that would otherwise leave the business. The cost is a chemical manufacturing operation with different skills, heavier environmental obligations and a scale requirement that a single finished dose maker may not fill. Integrated producers tend to do this selectively, for molecules where they hold large volume or where external supply is concentrated enough to be dangerous.